Relmada Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Relmada Therapeutics, Inc. (RLMD) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-79.98-98.79-157.04-125.75-59.46
Depreciation & Amortization0.000.000.000.000.00
Stock Based Compensation30.1943.8144.1940.4920.78
Change in Working Capital-1.583.0810.59-7.8610.85
Change in Accounts Receivable0.000.51-0.510.000.00
Change in Accounts Payable0.62-1.760.422.857.82
Change in Other Working Capital-2.214.3210.68-10.713.03
Other Operating Activities-0.3839.99-6.3541.1157.07
Net Cash from Operating Activities-51.76-51.66-103.80-91.87-27.81
Investing Activities
Capital Expenditures0.000.000.000.00182.05
Purchases of Investments-12.08-90.4619.73-54.12-34.45
Sales/Maturities of Investments63.64140.9267.03-54.12-34.45
Net Cash from Investing Activities51.5650.4519.73-54.12-34.45
Financing Activities
Debt Repayment0.000.00-0.050.00-0.11
Common Stock Issued0.250.0044.70187.9419.79
Other Financing Activities-0.29-0.100.322.6327.85
Net Cash from Financing Activities-0.04-0.1045.02187.9428.47
Summary
Net Change in Cash-0.23-1.30-39.0541.95-33.78
Cash at Beginning of Period4.095.4044.442.5036.28
Cash at End of Period3.864.095.4044.4436.28
Free Cash Flow-51.76-51.66-103.80-91.87-27.81
Supplemental Disclosures
Interest Paid0.000.000.000.000.00